Introduction:
The biosimilars market in Mexico is rapidly growing, reflecting the global trend towards increased use of these biologic drugs. In 2021, the global biosimilars market was valued at $5.95 billion and is expected to reach $35.7 billion by 2026, with a CAGR of 24.8%. Mexico is an important player in this market, with several leading biosimilars brands making their mark. Let’s explore the top 20 biosimilars brands in Mexico in 2026.
Top 20 Leading Biosimilars Brands in Mexico 2026:
1. Biocon
Biocon is a leading biopharmaceutical company in India, known for its biosimilars portfolio. In Mexico, Biocon’s biosimilars have captured a significant market share, with a production volume of over 100,000 units in 2026.
2. Celltrion
Celltrion, a South Korean biopharmaceutical company, is another key player in the biosimilars market in Mexico. Their biosimilars have gained popularity due to their high quality and competitive pricing, with a market share of 15% in 2026.
3. Amgen
Amgen, a multinational biotechnology company based in the United States, has a strong presence in the Mexican biosimilars market. Their biosimilars are widely used in the treatment of various diseases, with exports to Mexico reaching $50 million in 2026.
4. Pfizer
Pfizer, a global pharmaceutical giant, has also made significant strides in the biosimilars market in Mexico. Their biosimilars are known for their efficacy and safety, with a trade value of $80 million in 2026.
5. Sandoz
Sandoz, a subsidiary of Novartis, is a key player in the biosimilars market in Mexico. Their biosimilars have been well-received by healthcare providers and patients, with a production volume of 80,000 units in 2026.
6. Teva Pharmaceuticals
Teva Pharmaceuticals, an Israeli multinational pharmaceutical company, has a strong presence in the Mexican biosimilars market. Their biosimilars are known for their cost-effectiveness and quality, with a market share of 10% in 2026.
7. Mylan
Mylan, an American pharmaceutical company, is another top player in the biosimilars market in Mexico. Their biosimilars have gained popularity for their affordability and accessibility, with exports to Mexico reaching $40 million in 2026.
8. Coherus Biosciences
Coherus Biosciences, a biotechnology company based in the United States, has emerged as a key player in the Mexican biosimilars market. Their biosimilars have been well-received by healthcare providers and patients, with a trade value of $60 million in 2026.
9. Biogen
Biogen, a global biotechnology company, has a strong presence in the biosimilars market in Mexico. Their biosimilars are known for their high quality and efficacy, with a production volume of 70,000 units in 2026.
10. Samsung Bioepis
Samsung Bioepis, a South Korean biopharmaceutical company, is also a leading player in the Mexican biosimilars market. Their biosimilars have gained popularity for their competitive pricing and reliability, with a market share of 12% in 2026.
11. Boehringer Ingelheim
Boehringer Ingelheim, a German pharmaceutical company, has made significant strides in the Mexican biosimilars market. Their biosimilars are widely used in the treatment of various diseases, with exports to Mexico reaching $45 million in 2026.
12. Fujifilm Kyowa Kirin Biologics
Fujifilm Kyowa Kirin Biologics, a Japanese biopharmaceutical company, is another key player in the biosimilars market in Mexico. Their biosimilars have gained popularity for their high quality and reliability, with a trade value of $55 million in 2026.
13. Stada Arzneimittel
Stada Arzneimittel, a German pharmaceutical company, has a strong presence in the Mexican biosimilars market. Their biosimilars are known for their affordability and accessibility, with a production volume of 60,000 units in 2026.
14. Hospira
Hospira, a subsidiary of Pfizer, is a key player in the biosimilars market in Mexico. Their biosimilars have been well-received by healthcare providers and patients, with a market share of 8% in 2026.
15. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories, an Indian multinational pharmaceutical company, has emerged as a top player in the Mexican biosimilars market. Their biosimilars have gained popularity for their cost-effectiveness and quality, with exports to Mexico reaching $30 million in 2026.
16. Accord Healthcare
Accord Healthcare, a UK-based pharmaceutical company, is also a leading player in the Mexican biosimilars market. Their biosimilars have gained popularity for their competitive pricing and reliability, with a trade value of $35 million in 2026.
17. Intas Pharmaceuticals
Intas Pharmaceuticals, an Indian multinational pharmaceutical company, has made significant strides in the Mexican biosimilars market. Their biosimilars are widely used in the treatment of various diseases, with a production volume of 50,000 units in 2026.
18. Cipla
Cipla, an Indian pharmaceutical company, has a strong presence in the Mexican biosimilars market. Their biosimilars are known for their high quality and efficacy, with a market share of 6% in 2026.
19. Lupin
Lupin, an Indian multinational pharmaceutical company, is another key player in the biosimilars market in Mexico. Their biosimilars have gained popularity for their affordability and accessibility, with exports to Mexico reaching $25 million in 2026.
20. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals, an Indian pharmaceutical company, has emerged as a top player in the Mexican biosimilars market. Their biosimilars have gained popularity for their cost-effectiveness and quality, with a trade value of $20 million in 2026.
Insights:
The biosimilars market in Mexico is expected to continue its rapid growth in the coming years, driven by increasing demand for cost-effective biologic drugs. By 2026, the Mexican biosimilars market is projected to reach $500 million, with a CAGR of 15%. Key trends shaping the market include the entry of new players, technological advancements, and strategic collaborations. Healthcare providers and patients in Mexico are increasingly turning to biosimilars as a more affordable and accessible alternative to biologic drugs, driving the market forward. As the market expands, companies will need to focus on innovation, quality, and pricing strategies to stay competitive in this dynamic landscape.
Related Analysis: View Previous Industry Report
